Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

Key Takeaways Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away ...

Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...

The ASX 200 healthcare stock received another FDA approval for its cancer detection product. The post Up 113% in a year, ...

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...

B. Riley lowered the firm’s price target on Lantheus (LNTH) to $122 from $127 and keeps a Buy rating on the shares. Competitor Telix’s (TLX) ...

The Company's key achievements, aligned to its strategic pillars: Grow precision medicine: Prepared for launch of three new products TLX007-CDx (Gozellix®), TLX101-CDx (Pixclara®) and TLX250-CDx ...

Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug Application for Gozellix® gozetotide injection), Telix's next-generation ...